Corcept Therapeutics Inc. (NASDAQ:CORT) Director James N. Wilson sold 158,812 shares of Corcept Therapeutics stock in a transaction on Friday, November 11th. The shares were sold at an average price of $8.51, for a total value of $1,351,490.12. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Shares of Corcept Therapeutics Inc. (NASDAQ:CORT) opened at 9.74 on Tuesday. The company’s 50-day moving average price is $7.12 and its 200-day moving average price is $5.97. The firm has a market cap of $1.08 billion, a PE ratio of 249.74 and a beta of 1.64. Corcept Therapeutics Inc. has a 52-week low of $3.22 and a 52-week high of $10.00.

A number of research analysts have recently weighed in on the company. FBR & Co reiterated a “buy” rating on shares of Corcept Therapeutics in a report on Thursday, August 4th. Zacks Investment Research upgraded Corcept Therapeutics from a “hold” rating to a “buy” rating and set a $7.25 price target on the stock in a report on Tuesday, October 18th. Finally, Piper Jaffray Cos. set a $12.00 price target on Corcept Therapeutics and gave the company a “buy” rating in a report on Wednesday, October 19th.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of Montreal Can bought a new position in Corcept Therapeutics during the second quarter worth $100,000. Gotham Asset Management LLC increased its position in Corcept Therapeutics by 39.2% in the third quarter. Gotham Asset Management LLC now owns 20,908 shares of the company’s stock worth $136,000 after buying an additional 5,884 shares during the period. Campbell & CO Investment Adviser LLC increased its position in Corcept Therapeutics by 35.8% in the third quarter. Campbell & CO Investment Adviser LLC now owns 21,446 shares of the company’s stock worth $139,000 after buying an additional 5,652 shares during the period. Prudential Financial Inc. bought a new position in Corcept Therapeutics during the third quarter worth $141,000. Finally, BlackRock Group LTD increased its position in Corcept Therapeutics by 5.1% in the third quarter. BlackRock Group LTD now owns 22,573 shares of the company’s stock worth $147,000 after buying an additional 1,089 shares during the period. 41.31% of the stock is currently owned by institutional investors.

Corcept Therapeutics Company Profile

Corcept Therapeutics Inc is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company’s focus is on those disorders that are associated with a steroid hormone cortisol. Elevated levels and abnormal release patterns of cortisol have been implicated in a range of human disorders.

5 Day Chart for NASDAQ:CORT

Receive News & Stock Ratings for Corcept Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics Inc. and related stocks with our FREE daily email newsletter.